Yun Zhisheng (09678) released the “U2-Med Three Medical University Models”, the industry's first major professional model for the medical, medical insurance (including commercial insurance), and pharmaceutical fields

Zhitong Finance App News, Yun Zhisheng (09678) issued an announcement. Recently, the company completed an iterative upgrade of the medical model based on the U2 base model and officially released the “U2-Med Three Medical University Models” (this upgrade), the industry's first major professional model for the medical, medical insurance (including commercial insurance), and pharmaceutical fields. This upgrade further consolidates the company's model capabilities in the field of expertise and continues to promote technical iteration in high-value token scenarios. This model is expected to be widely embedded in core processes related to the digital collaboration of the three medical doctors, help accelerate the expansion of the company's large-scale model business, and form long-term and sustainable revenue contributions.

Relying on the company's U2 model base, U2-Med has achieved significant improvements in computational efficiency and intelligent execution. As the first industry-level model in the industry to integrate the full chain capabilities of the “Three Medicines”, U2-Med integrates the company's ten years of experience in the medical field, breaking down medical, medical insurance, pharmaceutical data and business silos, supporting the digital transformation of the three medical systems with integrated capabilities, and comprehensively covering professional task scenarios in the pan-medical field.

U2-Med penetrates the core business processes of the three medical institutions to bring practical capacity and efficiency improvements to clinicians, insurance practitioners and pharmaceutical practitioners: for doctors, the model has the ability to assist in diagnosis and treatment, generate medical records, and identify clinical and electronic document risks; for medical insurance and commercial insurance, the model can accurately identify questions such as excessive drug use, repeated charges, excessive diagnosis and treatment, support DRG/DIP compliance review, and help reviewers focus on key verification; for the pharmaceutical industry, the model assists subjects in pre-screening, verification of indications and contraindications, and risk reminders for combined drug use. This upgrade truly realizes the “clinical diagnosis and treatment - medical insurance payment - pharmaceutical supply” linkage and intelligent collaboration, and solves the core pain points of low cross-sector collaboration efficiency, fragmented management and high labor costs in one stop.

In the MedBench evaluation in July 2026, the U2-Med series model ranked first in both the full-modal large model and smart device lists. It also leads the “Three Medicine Comprehensive Benchmark” for real business, with a comprehensive score of 89.1 for the non-thinking model and 88.9 for the thinking model, including 93.3 for medical record generation and quality control, 94.1 for post-diagnosis and medication management, and 88.8 for medical insurance and commercial insurance tasks. The evaluation data fully proved that U2-Med is not only a general medical theoretical model, but also a commercial-grade professional model adapted to real business processes. Technical capabilities can be directly transformed into industrial implementation value.

After this upgrade, U2-Med will be deeply embedded in the broader business links of the Three Medical Companies, creating higher industrial value with “expert level” capabilities, while replacing repetitive work and unleashing the professional potential of the Three Medicine practitioners. The company will also continue to promote its large-scale implementation in the three medical fields, accelerate the accumulation of industrial data and the positive flywheel of model iteration, continue to raise business barriers, and inject long-term momentum into the continuous release and commercialization of high-value tokens.

The company firmly believes that the evolution of technology will always follow the path of inclusiveness; the ultimate vision of AGI is to protect and enhance a wide range of people's livelihood and welfare. This is where our company has been deeply involved in the medical field for more than ten years — transforming cutting-edge intelligence into the core driving force for protecting people's livelihood and health and empowering industrial upgrading, and implementing the value concept of “intelligence for good” with the power of “intelligence and upward”.